17 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.
Aventis Pharma
11
Fine Tuning of physico-chemical parameters to optimise a new series of novobiocin analogues.
Aventis Pharma
11
Principles governing the binding of a class of non-peptidic inhibitors to the SH2 domain of src studied by X-ray analysis.
Aventis Pharma
7
Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
Aventis Pharma
65
Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors.
Aventis Pharma
43
Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein.
Aventis Pharma
30
Discovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures.
Aventis Pharma
2
Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.
Aventis Pharma
14
Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY.
Aventis Pharma
9
Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors.
Aventis Pharma
11
An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
Aventis Pharma
1
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
Aventis Pharma
28
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
Aventis Pharma
4
Crystal structures of human factor Xa complexed with potent inhibitors.
Aventis Pharma
5
Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.
Aventis Pharma